Related references
Note: Only part of the references are listed.Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer
U. A. Matulonis et al.
ANNALS OF ONCOLOGY (2017)
Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis
Forest H. Andrews et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas
S. K. A. Divakar et al.
LEUKEMIA (2016)
Dual Kinase-Bromodomain Inhibitors in Anticancer Drug Discovery: A Structural and Pharmacological Perspective
Luca Carlino et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy
Elias E. Stratikopoulos et al.
CANCER CELL (2015)
Synthesis and Cancer Stem Cell-Based Activity of Substituted 5-Morpholino-7H-thieno[3,2-b]pyran-7-ones Designed as Next Generation PI3K Inhibitors
Guillermo A. Morales et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
Johanna C. Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations
Filip Janku et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Selective inhibition of BET bromodomains
Panagis Filippakopoulos et al.
NATURE (2010)
Share Paper
